Mainolfi Nello's Form 4 filing
Kymera Therapeutics, Inc. (KYMR) · filed Jul 9, 2021
- Accession no.
- 0001209191-21-046174
- Filed
- Jul 9, 2021
- Trade date
- Jul 8, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.39M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mainolfi NelloCIK 0001821189 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 8, 2021 | Common Stock | MOption exerciseAcquired | +48,000 | $2.08 | +$99,840 | 500,199 | Direct | |
| Jul 8, 2021 | Common Stock | SSaleDisposed | −17,230 | $49.15F2 | −$846,854.5 | 482,969 | Direct | |
| Jul 8, 2021 | Common Stock | SSaleDisposed | −23,803 | $49.71F3 | −$1,183,247.13 | 459,166 | Direct | |
| Jul 8, 2021 | Common Stock | SSaleDisposed | −6,372 | $50.96F4 | −$324,717.12 | 452,794 | Direct | |
| Jul 8, 2021 | Common Stock | SSaleDisposed | −595 | $51.64F5 | −$30,725.8 | 452,199 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 8, 2021 | Common Stock | MOption exerciseDisposed | −48,000 | $0.00 | $0 | 126,725 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $48.44 to $49.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $49.44 to $50.42. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.45 to $51.44. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.60 to $51.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.